eIF4E-Binding Peptides for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting eIF4E for cancer treatment face challenges due to emerging resistance mechanisms and the need for distinct mechanisms of action.
Innovation Solution
Development of a peptide with the amino acid sequence CEX1GX2X3X4X5C, where X1, X2, X3, X4, and X5 are specific amino acids, forming a disulphide bond and binding to eIF4E with high affinity, thereby inhibiting its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds targeting signalling pathways upstream of eIF4E are used, then eIF4E activity can be regulated, but resistance mechanisms emerge reducing treatment effectiveness
Solution Approach 1:
The patent uses eIF4E binding peptides as intermediaries that directly bind to eIF4E at its cap-binding site, circumventing the upstream signalling pathways that have developed resistance mechanisms. This intermediary approach allows regulation of eIF4E activity without engaging the resistant upstream pathways.
Solution Approach 2:
Instead of targeting upstream regulators of eIF4E (the conventional approach), the patent inverts the strategy by directly targeting eIF4E itself with binding peptides. This reversal of the targeting approach avoids resistance mechanisms that have developed against upstream pathway inhibitors.
2Reliability
If eIF4E binding peptides are designed to disrupt cap-dependent translation, then cancer cell proliferation is inhibited, but high manufacturing precision is required for the peptide sequence
Solution Approach 1:
The patent employs systematic variation of amino acid residues at specific positions (X1, X2, X3, X4, X5) to optimize peptide binding affinity and selectivity. This parameter optimization approach allows identification of sequences with enhanced therapeutic effect while maintaining feasible manufacturing requirements.
Solution Approach 2:
The patent applies specific amino acid constraints at particular positions within the peptide sequence (e.g., X1 from T/M/L, X2/X3 from hydrophobic/aromatic groups) to achieve optimal binding to eIF4E. This localized optimization ensures high therapeutic effectiveness without requiring absolute precision across the entire sequence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively binds to eIF4E, disrupting its cap-dependent translation activity, which is critical for cancer cell proliferation, thus providing a potential therapeutic approach for cancer treatment.
Implementation Method 1
wherein the two cysteine residues are joined by a disulphide bond
Data Source
AI summary
A peptide that binds to elongation initiation factor 4E (eIF4E) comprising the amino acid sequence CEX1GX2X3X4X5C (SEQ ID NO: 1), where X1 is an amino acid selected from the group consisting of threonine (T), methionine (M) or leucine (L), X2 and X3 is an amino acid selected from the group consisting of phenylalanine (F), modified phenylalanine and tyrosine (Y), X4 and X5 is any amino acid, wherein the two cysteine residues are joined by a disulphide bond. Further, pharmaceutical compositions and uses of the peptide, and pharmaceutical compositions are provided.